Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash & Equivalents (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Cash & Equivalents for 7 consecutive years, with $86.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 86.9% year-over-year to $86.1 million, compared with a TTM value of $86.1 million through Sep 2025, down 86.9%, and an annual FY2024 reading of $227.4 million, down 5.09% over the prior year.
  • Cash & Equivalents was $86.1 million for Q3 2025 at Autolus Therapeutics, down from $123.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $758.5 million in Q1 2024 and bottomed at $86.1 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $328.4 million, with a median of $268.6 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 156.25% in 2024, then plummeted 87.37% in 2025.
  • Year by year, Cash & Equivalents stood at $310.3 million in 2021, then rose by 23.23% to $382.4 million in 2022, then plummeted by 37.36% to $239.6 million in 2023, then decreased by 5.09% to $227.4 million in 2024, then crashed by 62.13% to $86.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for AUTL at $86.1 million in Q3 2025, $123.8 million in Q2 2025, and $95.8 million in Q1 2025.